Cholinesterase is a family of enzymes that break down acetylcholine, one of the body’s most important chemical messengers. Every time a nerve signals a muscle to contract or sends a message to another nerve cell, acetylcholine carries that signal across the gap between cells. Cholinesterase’s job is to clear that signal away almost instantly, splitting acetylcholine into two inactive pieces (choline and acetic acid) so the system can reset and fire again.
There are two main types of cholinesterase in the body, and they show up in different places, serve slightly different purposes, and matter in different medical situations.
The Two Types of Cholinesterase
The first type, acetylcholinesterase (AChE), is the one that does the heavy lifting at nerve junctions. It sits on the surfaces of nerve synapses, neuromuscular junctions, and red blood cell membranes. Its entire purpose is speed: it breaks down acetylcholine so rapidly that a nerve-to-muscle signal lasts only milliseconds before being cleared. Without this enzyme working properly, acetylcholine would pool in the junction, overstimulating the muscle or nerve on the receiving end.
The second type, butyrylcholinesterase (BChE), is sometimes called pseudocholinesterase. It’s produced by the liver and circulates mainly in blood plasma, though it also appears in the brain’s white matter, the pancreas, and the intestinal lining. Its biological role is less precisely understood than AChE’s, but it plays a critical part in metabolizing certain drugs and serves as a useful marker of liver health.
How It Works at the Nerve Junction
When a nerve impulse reaches the end of a nerve fiber, it triggers the release of acetylcholine into the tiny gap (synapse) between the nerve and its target, whether that’s a muscle fiber, another nerve, or a gland. Acetylcholine crosses the gap, binds to receptors on the other side, and delivers the “go” signal. If it lingered, the target would keep firing uncontrollably.
Cholinesterase prevents that. The enzyme’s active site grabs the acetylcholine molecule, snaps the chemical bond holding it together, and releases choline and acetic acid. The choline gets recycled back into the nerve ending to make fresh acetylcholine. This entire cycle takes just a few milliseconds, which is why your muscles can make fine, controlled movements instead of locking into sustained contractions.
Why Doctors Test Cholinesterase Levels
A standard blood test measures cholinesterase activity. Normal values typically fall between 3,100 and 6,500 units per liter, though labs vary slightly. Doctors order this test for two main reasons: to check for toxic exposure and to evaluate liver function.
Pesticide and Chemical Exposure
Organophosphate and carbamate pesticides work by blocking cholinesterase. Farmworkers, pest control operators, and others who handle these chemicals are sometimes monitored with regular blood tests. A baseline reading is taken when the person has had no recent exposure, and subsequent tests are compared against it. A 15 to 25 percent drop from baseline indicates slight poisoning. A 25 to 35 percent drop signals moderate poisoning, and a 35 to 50 percent decline indicates severe poisoning. If levels fall 30 percent or more below baseline, the person is typically pulled from all organophosphate and carbamate exposure until their levels recover.
The symptoms of cholinesterase inhibition from pesticides follow logically from what the enzyme does. When it can’t clear acetylcholine, signals pile up: muscles twitch or cramp, glands overproduce saliva and tears, pupils constrict, and in serious cases, the muscles that control breathing can fail.
Liver Function
Because butyrylcholinesterase is manufactured by the liver, low levels can signal that the liver isn’t producing proteins normally. In this way, it works similarly to albumin and clotting factors as an indicator of liver biosynthetic health. Low pseudocholinesterase levels are inversely associated with the severity of liver disease, meaning worse liver function generally produces lower enzyme levels. The decline happens through two mechanisms: the damaged liver makes less of the enzyme, and the enzyme’s activity itself is reduced. Conditions like hepatitis C infection, liver cancer, cirrhosis, and protein-energy malnutrition can all drive levels down.
Pseudocholinesterase Deficiency and Anesthesia
One of the most clinically significant cholinesterase issues is an inherited deficiency of pseudocholinesterase. This matters primarily during surgery. A common muscle relaxant used during general anesthesia is metabolized by pseudocholinesterase. In people with normal enzyme levels, this drug paralyzes muscles for about 3 minutes, just long enough to place a breathing tube. In someone with a genetic deficiency, the drug isn’t broken down on schedule, and paralysis can last far longer.
People who carry one copy of the defective gene (heterozygotes) typically experience about a 30 percent increase in how long the paralysis lasts. People who carry two copies (homozygotes) can remain paralyzed for 2 to 3 hours from a dose that would wear off in minutes for most people. The main danger is respiratory failure, since the person’s breathing muscles stay paralyzed and they need mechanical ventilation until the drug eventually clears.
The most common genetic variant, known as the K-variant, reduces plasma enzyme activity by about 33 percent. A different variant, called atypical BChE, is the one most frequently linked to prolonged paralysis after anesthesia. There are also “silent” variants that produce either a non-functional enzyme or no enzyme at all. Notably, loss-of-function mutations have been found only in the gene for butyrylcholinesterase, not in the gene for acetylcholinesterase, likely because complete loss of AChE would be incompatible with normal nerve function.
Most people with pseudocholinesterase deficiency have no idea they carry it until they undergo anesthesia. Once identified, it’s flagged in their medical record so that alternative muscle relaxants can be used in future surgeries.
Cholinesterase Inhibitors in Alzheimer’s Treatment
The same principle that makes organophosphate poisoning dangerous has been harnessed, in a much more controlled way, to treat Alzheimer’s disease. In Alzheimer’s, the brain loses cholinergic neurons, the ones that use acetylcholine to communicate. The result is a shortage of acetylcholine in key brain regions involved in memory and cognition.
Cholinesterase inhibitors slow the breakdown of whatever acetylcholine the brain still produces, keeping it active at synapses for longer. Three are commonly prescribed: donepezil and galantamine, which selectively target acetylcholinesterase, and rivastigmine, which blocks both acetylcholinesterase and butyrylcholinesterase. These medications don’t stop the disease from progressing, but they provide symptomatic benefit across memory, thinking, and daily functioning, particularly in mild to moderate stages. They remain the primary approved pharmacologic approach for Alzheimer’s in the United States.
Galantamine has an additional mechanism: it also modulates nicotinic receptors in the brain, which may enhance the effect of the acetylcholine that’s preserved. Donepezil interacts with similar receptors through a different binding site. These extra actions are one reason the three drugs, despite sharing a basic mechanism, can produce somewhat different responses in different patients.